Guan Xiao-feng, Hamedani Mohammad K, Adeyinka Adewale, Walker Christina, Kemp Angela, Murphy Leigh C, Watson Peter H, Leygue Etienne
Departments of Biochemistry and Medical Genetics, University of Manitoba, Faculty of Medicine, Winnipeg, Manitoba, Canada, R3EOW3.
Endocrine. 2003 Aug;21(3):245-50. doi: 10.1385/ENDO:21:3:245.
Mammaglobin (SCGB2A2) is a breast-specific member of the secretoglobin (SCGB) gene family. SCGB2A2 has previously been found overexpressed in breast tumors but possible associations between its expression and established prognostic tumor characteristics such as the levels of estrogen and progesterone receptors have not yet been investigated. We evaluated SCGB2A2 expression at the mRNA and at the protein level by reverse-transcription polymerase chain reaction and immunocytochemistry in 52 and 32 breast tumors, respectively. Both SCGB2A2 mRNA and protein expression were significantly higher in estrogen-receptor-positive compared to estrogen-receptor-negative tumors (Mann- Whitney rank sum test, p = 0.04; chi-square test, p = 0.01; respectively). In contrast, SCGB2A2 expression did not correlate with progesterone receptor levels or Nottingham grade. As estrogen and antiestrogen treatment of estrogen-positive breast cancer cell lines does not modify SCGB2A2 expression we suggest that SCGB2A2 may be a new independent breast cancer prognostic marker.
乳腺珠蛋白（SCGB2A2）是分泌球蛋白（SCGB）基因家族的一个乳腺特异性成员。此前已发现SCGB2A2在乳腺肿瘤中过表达，但尚未对其表达与雌激素和孕激素受体水平等已确定的肿瘤预后特征之间可能存在的关联进行研究。我们分别通过逆转录聚合酶链反应和免疫细胞化学方法，对52例和32例乳腺肿瘤的SCGB2A2 mRNA和蛋白水平表达进行了评估。与雌激素受体阴性肿瘤相比，雌激素受体阳性肿瘤中的SCGB2A2 mRNA和蛋白表达均显著更高（分别为Mann-Whitney秩和检验，p = 0.04；卡方检验，p = 0.01）。相反，SCGB2A2表达与孕激素受体水平或诺丁汉分级无关。由于雌激素阳性乳腺癌细胞系的雌激素和抗雌激素治疗并未改变SCGB2A2表达，我们认为SCGB2A2可能是一种新的独立的乳腺癌预后标志物。
